ABTB1, as an E3 ubiquitin ligase, suppresses Th17 cell differentiation and mitigates autoimmune inflammation by promoting STAT3 ubiquitination and degradation.

ABTB1 functions as an E3 ubiquitin ligase that suppresses Th17 cell differentiation by promoting STAT3 degradation, reducing autoimmune inflammation.

• Why it matters: Th17 cells are key drivers of autoimmune diseases, but mechanisms controlling their differentiation are not fully understood. Targeting these pathways could lead to new therapies.
• What they did: Researchers identified ABTB1 as a regulator of Th17 differentiation, demonstrating that neddylated ABTB1 mediates polyubiquitination of STAT3, leading to its degradation through the ubiquitin-proteasome pathway.
• The result: Loss of ABTB1 enhances Th17 responses and worsens colitis symptoms, suggesting ABTB1 as a promising therapeutic target for autoimmune conditions like IBD.